#FABP5

[medicomunicare]

Omega-6 amici del tumore mammario: ecco come fa l'acido linoleico a stimolare la crescita

L’acido linoleico (polinsaturo omega-6) è un nutriente derivato dalla dieta che è considerato essenziale nei mammiferi per supportare molteplici processi corporei. Tuttavia, l’abbondanza di questo grasso nella dieta “occidentale” è aumentata in modo significativo dagli anni ’50, in concomitanza con il maggiore utilizzo di oli di semi in cibi fritti e ultra-lavorati. Ciò ha portato a…

[darkmaga-returns]

By Nicolas Hulscher, MPH

The study titled, Direct sensing of dietary ω-6 linoleic acid through FABP5-mTORC1 signaling, was recently published in the journal Science:

RATIONALE ω-6 linoleic acid (LA) is the most abundant unsaturated fat in Western-style diets and is derived from animal products [grain-fed instead of grass-fed] and processed foods containing vegetable oils, such as safflower oil. Many case-controlled retrospective and prospective studies have been conducted that explore associations between ω-6 LA intake and breast cancer incidence, but the conclusions are often contradictory. Adding to this complexity is breast cancer heterogeneity: Patients are stratified into four main clinical subtypes on the basis of expression of hormone receptors or lack thereof, each with distinct molecular characteristics and therapeutic sensitivities. Because ω-6 LA is an essential nutrient, we hypothesized that the mTOR pathway senses and is activated by its availability, leading to increased breast cancer cell proliferation in a subtype-specific manner. RESULTS By leveraging an extensive panel of breast cancer cell lines and patient-derived xenograft (PDX) tumors, we observed that ω-6 LA could activate mTORC1 but only in models of triple-negative breast cancer (TNBC), which is the most aggressive subtype that lacks any targeted therapy. We found that levels of the lipid chaperone fatty acid–binding protein 5 (FABP5) were significantly higher in TNBC compared with hormone receptor–positive tumors and that FABP5 directly interacted with mTORC1 to regulate complex formation, substrate binding, and subcellular localization. Notably, we demonstrated the relevance of this FABP5-mTORC1 signaling pathway in vivo by feeding animals a diet enriched for safflower oil that promoted TNBC tumor growth. FABP5 and ω-6 PUFAs appear to trigger a “perfect storm” of nutrient-driven signaling events, and both factors are also elevated in the serum of newly diagnosed TNBC patients.

[leedsomics]

Single-nucleus transcriptomics reveal the cytological mechanism of conjugated linoleic acids in regulating intramuscular fat deposition

Conjugated linoleic acids (CLAs) can serve as a nutritional intervention to regulate quality, function and fat infiltration in skeletal muscles but the specific cytological mechanisms are still unknown. Here, we applied single-nucleus RNA-sequencing (snRNA-seq) to characterize the cytological mechanism of CLAs regulates fat infiltration in skeletal muscles based on pig models. We investigated the regulatory effects of CLAs on cell populations and molecular characteristics in pig muscles and found CLAs could promote the transformation of fast glycolytic myofibers into slow oxidative myofibers. We also observed three subpopulations including SCD+/DGAT2+, FABP5+/SIAH1+, and PDE4D+/PDE7B+ subclusters in adipocytes and CLAs could increase the percentage of SCD+/DGAT2+ adipocytes. RNA velocity analysis showed FABP5+/SIAH1+ and PDE4D+/PDE7B+ adipocytes could differentiate into SCD+/DGAT2+ adipocytes. We further verified the differentiated trajectory of mature adipocytes and identified PDE4D+/PDE7B+ adipocytes could differentiate into SCD+/DGAT2+ and FABP5+/SIAH1+ adipocytes by using high IMF content Laiwu pig models. The cell-cell communication analysis identified the interaction network between adipocytes and other subclusters such as fibro/adipogenic progenitors (FAPs). Pseudotemporal trajectory analysis and RNA velocity analysis also showed FAPs could differentiate into PDE4D+/PDE7B+ preadipocytes and we discovered the differentiated trajectory of preadipocytes into mature adipocytes. Besides, we found CLAs could promote FAPs differentiate into SCD+/DGAT2+ adipocytes via inhibiting c-Jun N-terminal kinase (JNK) signalling pathway in vitro. This study provides a foundation for regulating fat infiltration in skeletal muscles by using nutritional strategies and provides potential opportunities to serve pig as an animal model to study human fat infiltrated diseases. http://dlvr.it/T7dwm4

[bpod-bpod]

In a Bind

Multiple myeloma is a blood cancer affecting plasma cells, white blood cells that produce antibodies, causing them to multiply abnormally in the bone marrow. Right now, only half of patients can expect to survive five years after diagnosis, so better treatments are sorely needed. Promising targets include fatty acid-binding proteins (FABPs), a multi-functional family of proteins that can pick up lipids, involved in a variety of processes. A recent study found that cultured myeloma cells (pictured, their nuclei in blue) expressed high levels of one member in particular, FABP5 (in red); blocking it reduced cell proliferation, while patients with higher FABP5 levels tended to experience worse outcomes. Inhibiting FABPs more broadly appeared even more effective, improving survival in some mice with myeloma. To build on these results, further research needs to investigate why not all mice responded so well, and whether inhibiting FABPs would be safe and effective in humans.

Written by Emmanuelle Briolat

Image from work by Mariah Farrell and colleagues

Center for Molecular Medicine, Maine Health Institute for Research, Scarborough, ME, USA

Image originally published with a Creative Commons Attribution 4.0 International (CC BY 4.0)

Published in eLife, March 2023

You can also follow BPoD on Instagram, Twitter and Facebook

[marketnews2021]

The global peptide based cancer therapeutics market size is expected to reach USD 17.18 billion by 2027 according to a new study by Polaris Market Research. The report “Peptide Based Cancer Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Goserelin, Bortezomib, Leuprorelin, and Others); By Cancer Type (Lung, Breast, Colorectal, Prostrate, Skin, and Stomach Cancer); By Mode of Mechanism (Inhibitory, Necrosis Inducing, and Pro-Apoptotic Peptides), By Distribution Channel (Hospital, Retail, and Online Pharmacies), By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Peptides are compounds that are created by natural or artificial biological linking of amino acid monomers. Peptides are being widely used in therapeutics to treat several ailments, including cancer owing to their precision based nature, targeting solid tumor cells in the body. Peptide based cancer therapeutics have shown effective results against cancer as opposed to conventional cancer treatments, without much side effects.

Peptide based therapies in the treatment of cancer are majorly classified as pure play peptide therapy, vaccines based on peptide, and peptide conjugate nanomaterials. These therapies possess several advantages over others such as easy administration, specificity in targeting tumor tissues, fewer side effects as compared to drugs, and low cost of peptides.

Request for sample copy of this report @ https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market/request-for-sample

The factors propelling the market growth are the increasing prevalence of cancer across the world, cancer screening programs in emerging countries, and the high specificity of peptide based cancer vaccines. In 2016, according to analysis by NCA (National Cancer Center), 1,010,200 cancer cases were recorded, with 576,100 male patients and 434,100 women cases. The mortality rate in 2016 recorded a high with more than 374,000 cancer deaths in the country, particularly deaths associated with the most common colorectal cancer followed by gastric, lung, prostrate and breast cancers.

Market participants such as AstraZeneca PLC, Abbott, Allergan plc, Teva Pharmaceuticals, Pfizer Inc., Takeda Pharmaceutical, Amgen, Inc., Johnson & Johnson, AbbVie Inc., and Valeant Pharmaceuticals Inc., are some of the key players operating in the concerned market. In January 2020, Sony Brook University (SBU) extended its funding on FABP5 inhibitors to 2025 by demonstrating novel approach to treat last stage prostate cancer. According to the researchers of the SBU specific fatty acid binding protein (FABP) may be help in stopping cancer.

In June 2017, AstraZeneca along with National Cancer Institute Eleven entered into cooperative research and development agreement with Eleven Biotherapeutics to develop Vicinium in combination with AstraZeneca’s immune checkpoint inhibitor, Imfinzi to treat non-muscle invasive bladder cancer.

Polaris Market research has segmented the peptide based cancer therapeutics market report on the basis of drug type, cancer type, mode of mechanism, distribution channel, and region

Peptide Based Cancer Therapeutics Drug Type Outlook (Revenue – USD Million, 2016 – 2027)

Goserelin

Bortezomib

Leuprorelin

Others

Peptide Based Cancer Therapeutic Cancer Type Outlook (Revenue – USD Million, 2016 – 2027)

Lung Cancer

Breast Cancer

Colorectal Cancer

Prostate Cancer

Skin Cancer

Stomach Cancer

Peptide Based Cancer Therapeutics Mode of Action Outlook (Revenue – USD Million, 2016 – 2027)

Inhibitory

Necrosis Inducing

Pro-Apoptotic Peptides

Peptide Based Cancer Therapeutics Distribution Channel Outlook (Revenue – USD Million, 2016 – 2027)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Peptide Based Cancer Therapeutics Regional Outlook (Revenue – USD Million, 2016 – 2027)

North America

Europe

Asia Pacific

Central & South America

Middle East & Africa

U.S.

Canada

France

Germany

UK

Italy

Spain

Netherlands

Austria

China

India

Japan

Malaysia

South Korea

Indonesia

Mexico

Brazil

Argentina

UAE

Saudi Arabia

Israel

South Africa

.Request for Discount on This Report  @ https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market/request-for-discount-pricing

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com

[udaycmi]

The global peptide based cancer therapeutics market size is expected to reach USD 17.18 billion by 2027 according to a new study by Polaris Market Research. The report “Peptide Based Cancer Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Goserelin, Bortezomib, Leuprorelin, and Others); By Cancer Type (Lung, Breast, Colorectal, Prostrate, Skin, and Stomach Cancer); By Mode of Mechanism (Inhibitory, Necrosis Inducing, and Pro-Apoptotic Peptides), By Distribution Channel (Hospital, Retail, and Online Pharmacies), By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Peptides are compounds that are created by natural or artificial biological linking of amino acid monomers. Peptides are being widely used in therapeutics to treat several ailments, including cancer owing to their precision based nature, targeting solid tumor cells in the body. Peptide based cancer therapeutics have shown effective results against cancer as opposed to conventional cancer treatments, without much side effects.

Get Sample copy of this report: https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market/request-for-sample

Peptide based therapies in the treatment of cancer are majorly classified as pure play peptide therapy, vaccines based on peptide, and peptide conjugate nanomaterials. These therapies possess several advantages over others such as easy administration, specificity in targeting tumor tissues, fewer side effects as compared to drugs, and low cost of peptides.

The factors propelling the market growth are the increasing prevalence of cancer across the world, cancer screening programs in emerging countries, and the high specificity of peptide based cancer vaccines. In 2016, according to analysis by NCA (National Cancer Center), 1,010,200 cancer cases were recorded, with 576,100 male patients and 434,100 women cases. The mortality rate in 2016 recorded a high with more than 374,000 cancer deaths in the country, particularly deaths associated with the most common colorectal cancer followed by gastric, lung, prostrate and breast cancers.

Market participants such as AstraZeneca PLC, Abbott, Allergan plc, Teva Pharmaceuticals, Pfizer Inc., Takeda Pharmaceutical, Amgen, Inc., Johnson & Johnson, AbbVie Inc., and Valeant Pharmaceuticals Inc., are some of the key players operating in the concerned market. In January 2020, Sony Brook University (SBU) extended its funding on FABP5 inhibitors to 2025 by demonstrating novel approach to treat last stage prostate cancer. According to the researchers of the SBU specific fatty acid binding protein (FABP) may be help in stopping cancer.

Request Discount: https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com

[blogpicturesdonalexander]

Иммунологи обобщают функции семейства белков?

Иллюстрация функций белков, связывающих жирные кислоты (FABP).

  Связывающие жирные кислоты белки (FABP) служат в качестве шаперона, координирующего транспорт жирных кислот и других молекул между клетками. Известно, что по крайней мере девять типов FABP, идентифицированных тканями и органами, в которых они были впервые обнаружены, играют многочисленные роли в метаболизме липидов. Хотя они отвечают за важные функции по поддержанию здоровья, ожирение может привести к более высокому уровню этих белков, вызывая болезнь. Когда люди страдают ожирением, FABPs в различных клетках и тканях активируются, что приводит к изменениям в метаболизме липидов и ответных реакциях. Большую роль FABP, уделяют в изучении и развитии хронического воспаления, ожирения и рака. Исследования в моей лаборатории показывают, что члены семейства FABP, особенно FABP4 и FABP5, играют решающую роль в опосредовании заболеваний, связанных с ожирением, путем регулирования функций иммунных клеток. Таким образом, наши исследования FABP не только раскрывают основные механизмы, с помощью которых ожирение подрывает здоровье человека, но и предоставляют новые цели для новых иммунотерапевтических стратегий для клиник. В заключении добавлю, что необходимо, как можно быстрее внести свой вклад в борьбу с ожирением и сопутствующим заболеваниям.

  понедельник, 24 августа 2020, 14:18:53

[janepwilliams87]

FABP5 inhibitors as a novel strategy of modulating the endocannabinoid system

Modulating the endocannabinoid system for its vast therapeutic potential is among the most promising fields of current research strategies. Alongside the development of phytocannabinoids for medicinal purposes, another strategy of pharmaceutical companies is to increase the level of endocannabinoids like anandamide (AEA) within our body. This has previously been approached through inhibiting the degradation enzymes […]

FABP5 inhibitors as a novel strategy of modulating the endocannabinoid system is a post from: Marijuana Business Daily: Financial, Legal & Cannabusiness news for cannabis entrepreneurs

from Updates By Jane https://mjbizdaily.com/fabp5-inhibitors-as-a-novel-strategy-of-modulating-the-endocannabinoid-system/

[rnomics]

IJMS, Vol. 18, Pages 21: Long Non-Coding #RNA Profiling in a Non-Alcoholic Fatty Liver Disease Rodent Model: New Insight into Pathogenesis

Non-alcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic liver diseases worldwide with an unclear mechanism. Long non-coding #RNAs (l#ncRNAs) have recently emerged as important regulatory molecules. To better understand NAFLD pathogenesis, l#ncRNA and messenger #RNA (#mRNA) microarrays were conducted in an NAFLD rodent model. Potential target genes of significantly changed l#ncRNA were predicted using cis/trans-regulatory algorithms. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were then performed to explore their function. In the current analysis, 89 upregulated and 177 downregulated #mRNAs were identified, together with 291 deregulated l#ncRNAs. Bioinformatic analysis of these #RNAs has categorized these #RNAs into pathways including arachidonic acid metabolism, circadian rhythm, linoleic acid metabolism, peroxisome proliferator-activated receptor (PPAR) signaling pathway, sphingolipid metabolism, steroid biosynthesis, tryptophan metabolism and tyrosine metabolism were compromised. Quantitative polymerase chain reaction (qPCR) of representative nine #mRNAs and eight l#ncRNAs (named fatty liver-related l#ncRNA, FLRL) was conducted and this verified previous microarray results. Several l#ncRNAs, such as FLRL1, FLRL6 and FLRL2 demonstrated to be involved in circadian rhythm targeting period circadian clock 3 (Per3), Per2 and aryl hydrocarbon receptor nuclear translocator-like (Arntl), respectively. While FLRL8, FLRL3 and FLRL7 showed a potential role in PPAR signaling pathway through interaction with fatty acid binding protein 5 (Fabp5), lipoprotein lipase (Lpl) and fatty acid desaturase 2 (Fads2). Functional experiments showed that interfering of l#ncRNA FLRL2 expression affected the expression of predicted target, circadian rhythm gene Arntl. Moreover, both FLRL2 and Arntl were downregulated in the NAFLD cellular model. The current study identified l#ncRNA and corresponding #mRNA in NAFLD, providing new insight into the pathogenesis of NAFLD. Moreover, we identified a new l#ncRNA FLRL2, that might participate NAFLD pathogenesis mediated by Arntl. http://bit.ly/2jW1zBD #MDPI

[latestarticle]

Peptide Based Cancer Therapeutics Market 2020: Future Challenges and Industry Growth Outlook 2027

Global Peptide Based Cancer Therapeutics Market: Trending in 2021

New York, NY 9 June 2021: The global peptide based cancer therapeutics market size is expected to reach USD 17.18 billion by 2027 according to a new study by Polaris Market Research. The report “Peptide Based Cancer Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Goserelin, Bortezomib, Leuprorelin, and Others); By Cancer Type (Lung, Breast, Colorectal, Prostrate, Skin, and Stomach Cancer); By Mode of Mechanism (Inhibitory, Necrosis Inducing, and Pro-Apoptotic Peptides), By Distribution Channel (Hospital, Retail, and Online Pharmacies), By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Peptides are compounds that are created by natural or artificial biological linking of amino acid monomers. Peptides are being widely used in therapeutics to treat several ailments, including cancer owing to their precision based nature, targeting solid tumor cells in the body. Peptide based cancer therapeutics have shown effective results against cancer as opposed to conventional cancer treatments, without much side effects.

Peptide based therapies in the treatment of cancer are majorly classified as pure play peptide therapy, vaccines based on peptide, and peptide conjugate nanomaterials. These therapies possess several advantages over others such as easy administration, specificity in targeting tumor tissues, fewer side effects as compared to drugs, and low cost of peptides.

Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market/request-for-sample

The factors propelling the market growth are the increasing prevalence of cancer across the world, cancer screening programs in emerging countries, and the high specificity of peptide based cancer vaccines. In 2016, according to analysis by NCA (National Cancer Center), 1,010,200 cancer cases were recorded, with 576,100 male patients and 434,100 women cases. The mortality rate in 2016 recorded a high with more than 374,000 cancer deaths in the country, particularly deaths associated with the most common colorectal cancer followed by gastric, lung, prostrate and breast cancers.

Market participants such as AstraZeneca PLC, Abbott, Allergan plc, Teva Pharmaceuticals, Pfizer Inc., Takeda Pharmaceutical, Amgen, Inc., Johnson & Johnson, AbbVie Inc., and Valeant Pharmaceuticals Inc., are some of the key players operating in the concerned market. In January 2020, Sony Brook University (SBU) extended its funding on FABP5 inhibitors to 2025 by demonstrating novel approach to treat last stage prostate cancer. According to the researchers of the SBU specific fatty acid binding protein (FABP) may be help in stopping cancer.

In June 2017, AstraZeneca along with National Cancer Institute Eleven entered into cooperative research and development agreement with Eleven Biotherapeutics to develop Vicinium in combination with AstraZeneca’s immune checkpoint inhibitor, Imfinzi to treat non-muscle invasive bladder cancer.

To get Incredible Discounts on this Premium Report, Click At: https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market/request-for-discount-pricing

Polaris Market research has segmented the peptide based cancer therapeutics market report on the basis of drug type, cancer type, mode of mechanism, distribution channel, and region

Peptide Based Cancer Therapeutics Drug Type Outlook (Revenue – USD Million, 2016 – 2027)

Goserelin

Bortezomib

Leuprorelin

Others

Peptide Based Cancer Therapeutic Cancer Type Outlook (Revenue – USD Million, 2016 – 2027)

Lung Cancer

Breast Cancer

Colorectal Cancer

Prostate Cancer

Skin Cancer

Stomach Cancer

Peptide Based Cancer Therapeutics Mode of Action Outlook (Revenue – USD Million, 2016 – 2027)

Inhibitory

Necrosis Inducing

Pro-Apoptotic Peptides

Peptide Based Cancer Therapeutics Distribution Channel Outlook (Revenue – USD Million, 2016 – 2027)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Have Any Query or Specific Requirement? Request for customization: https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market/request-for-customization

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.

Contact Us:

Polaris Market Research

Phone: 1–646–568–9980

Email: sales@polarismarketresearch.com

Web: http://www.polarismarketresearch.com

[karishmamulani]

Peptide Based Cancer Therapeutics Market Size, PESTEL Analysis, SWOT Study and Competitive Landscape Forecast 2027

The global peptide based cancer therapeutics market size is expected to reach USD 17.18 billion by 2027 according to a new study by Polaris Market ResearchPeptides are compounds that are created by natural or artificial biological linking of amino acid monomers. Peptides are being widely used in therapeutics to treat several ailments, including cancer owing to their precision based nature, targeting solid tumor cells in the body. Peptide based cancer therapeutics have shown effective results against cancer as opposed to conventional cancer treatments, without much side effects.

Peptide based therapies in the treatment of cancer are majorly classified as pure play peptide therapy, vaccines based on peptide, and peptide conjugate nanomaterials. These therapies possess several advantages over others such as easy administration, specificity in targeting tumor tissues, fewer side effects as compared to drugs, and low cost of peptides.

Download Sample Copy : https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market/request-for-sample

Market participants such as AstraZeneca PLC, Abbott, Allergan plc, Teva Pharmaceuticals, Pfizer Inc., Takeda Pharmaceutical, Amgen, Inc., Johnson & Johnson, AbbVie Inc., and Valeant Pharmaceuticals Inc., are some of the key players operating in the concerned market. In January 2020, Sony Brook University (SBU) extended its funding on FABP5 inhibitors to 2025 by demonstrating novel approach to treat last stage prostate cancer. According to the researchers of the SBU specific fatty acid binding protein (FABP) may be help in stopping cancer.

In June 2017, AstraZeneca along with National Cancer Institute Eleven entered into cooperative research and development agreement with Eleven Biotherapeutics to develop Vicinium in combination with AstraZeneca’s immune checkpoint inhibitor, Imfinzi to treat non-muscle invasive bladder cancer.

The factors propelling the market growth are the increasing prevalence of cancer across the world, cancer screening programs in emerging countries, and the high specificity of peptide based cancer vaccines. In 2016, according to analysis by NCA (National Cancer Center), 1,010,200 cancer cases were recorded, with 576,100 male patients and 434,100 women cases. The mortality rate in 2016 recorded a high with more than 374,000 cancer deaths in the country, particularly deaths associated with the most common colorectal cancer followed by gastric, lung, prostrate and breast cancers.

Have some specific queries about this report, our team of analyst will be glad to help! Click here : https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market/speak-to-analyst

[healthtimetaylor]

Pterostilbene inhibits adipocyte conditioned-medium-induced colorectal cancer cell migration.

PMID:  J Agric Food Chem. 2019 Aug 16. Epub 2019 Aug 16. PMID: 31419115 Abstract Title:  Pterostilbene inhibits adipocyte conditioned-medium-induced colorectal cancer cell migration through targeting FABP5-related signaling pathway. Abstract:  Pterostilbene (PTS) is a phenolic compound with diverse pharmacologic activities. However, its potential for inhibiting obesity-related CRC remains unclear. Our study evaluated the mechanism of inhibitory effects of PTS on adipocyte conditioned-medium (aCM)-induced malignant transformation in HT-29 colorectal adenocarcinoma cells. The results demonstrated that PTS could downregulate the expression of aCM-induced fatty acid-binding protein 5 (FABP5) and pro-metastasis factors such as vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP2), MMP9, and extracellular tumor necrosis factor alpha (TNF-α) via inhibiting aCM-induced nuclear factor-kappa B (NF-κB), β-catenin, and peroxisome proliferator-activated receptor γ (PPAR-γ). Moreover, PTS can suppress aCM-stimulated phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), p38 mitogen-activated protein kinase (p38 MAPK), extracellularsignal-regulated kinase (ERK), and c-Jun N-terminal kinases 1/2 (JNK 1/2) signaling pathways activation that are upstream of NF-B, β-catenin, and PPAR-γ. Therefore, we suggest that PTS could alleviate adiposity-induced cachexia in CRC via inhibiting cell migration through downregulating FABP5 gene expression.

read more

[ruggerorespigo]

Novel role of protein in important pathways that lead to cancer malignancy

Researchers have revealed for the first time that a specific protein, the fatty acid-binding protein 5 (FABP5), plays a critical role in the development and metastasis of highly aggressive prostate and breast cancer cells. They point out that a better understanding of the molecular pathways of specific cancers is a step in the direction of finding more effective therapeutic targets. Latest Science News -- ScienceDaily https://www.sciencedaily.com/releases/2018/08/180830095413.htm

[cancersfakianakis1]

LNMICC Promotes Nodal Metastasis of Cervical Cancer by Reprogramming Fatty Acid Metabolism

Cancer spread to lymph nodes predicts poor survival but underlying mechanisms remain little understood. In this study, we show that overexpression of the long noncoding RNA LNMICC associates with lymph node metastasis of primary cervical cancer, where it serves as an independent high-risk factor in patient survival. Functional investigations demonstrated that LNMICC promoted lymph node metastasis by reprogramming fatty acid metabolism, by recruiting the nuclear factor NPM1 to the promoter of the fatty acid binding protein FABP5. We also found that the prometastatic effects of LNMICC were directly targeted and suppressed by miR-190. Our results establish a new mechanism of lymph node metastasis and highlight LNMICC as a candidate prognostic biomarker and therapeutic target in cervical cancer.Significance: These results establish the role of a novel long noncoding RNA in lymph node metastasis, with implications as a candidate prognostic biomarker and therapeutic target in cervical cancer. Cancer Res; 78(4); 877–90. ©2017 AACR. http://ift.tt/2C3PXWa

[udaycmi]

The global peptide based cancer therapeutics market size is expected to reach USD 17.18 billion by 2027 according to a new study by Polaris Market Research. The report “Peptide Based Cancer Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Type (Goserelin, Bortezomib, Leuprorelin, and Others); By Cancer Type (Lung, Breast, Colorectal, Prostrate, Skin, and Stomach Cancer); By Mode of Mechanism (Inhibitory, Necrosis Inducing, and Pro-Apoptotic Peptides), By Distribution Channel (Hospital, Retail, and Online Pharmacies), By Regions; Segment Forecast, 2020 –2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Peptides are compounds that are created by natural or artificial biological linking of amino acid monomers. Peptides are being widely used in therapeutics to treat several ailments, including cancer owing to their precision based nature, targeting solid tumor cells in the body. Peptide based cancer therapeutics have shown effective results against cancer as opposed to conventional cancer treatments, without much side effects.

Get Sample copy of this report: https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market/request-for-sample

Peptide based therapies in the treatment of cancer are majorly classified as pure play peptide therapy, vaccines based on peptide, and peptide conjugate nanomaterials. These therapies possess several advantages over others such as easy administration, specificity in targeting tumor tissues, fewer side effects as compared to drugs, and low cost of peptides.

The factors propelling the market growth are the increasing prevalence of cancer across the world, cancer screening programs in emerging countries, and the high specificity of peptide based cancer vaccines. In 2016, according to analysis by NCA (National Cancer Center), 1,010,200 cancer cases were recorded, with 576,100 male patients and 434,100 women cases. The mortality rate in 2016 recorded a high with more than 374,000 cancer deaths in the country, particularly deaths associated with the most common colorectal cancer followed by gastric, lung, prostrate and breast cancers.

Market participants such as AstraZeneca PLC, Abbott, Allergan plc, Teva Pharmaceuticals, Pfizer Inc., Takeda Pharmaceutical, Amgen, Inc., Johnson & Johnson, AbbVie Inc., and Valeant Pharmaceuticals Inc., are some of the key players operating in the concerned market. In January 2020, Sony Brook University (SBU) extended its funding on FABP5 inhibitors to 2025 by demonstrating novel approach to treat last stage prostate cancer. According to the researchers of the SBU specific fatty acid binding protein (FABP) may be help in stopping cancer.

Request Discount: https://www.polarismarketresearch.com/industry-analysis/peptide-based-cancer-therapeutics-market/request-for-discount-pricing

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises. We at Polaris are obliged to serve our diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world

Contact us

Polaris Market Research

Phone: 1-646-568-9980

Email: sales@polarismarketresearch.com

Web: www.polarismarketresearch.com

[epigen-papers]

Cigarette smoke inhibits LPS-induced FABP5 expression by preventing c-Jun binding to the FABP5 promoter.

Pubmed: http://dlvr.it/PFLSQs